Andrew Moon
@andrewmmoon.bsky.social
Hepatologist at researcher at UNC GI, UNC Liver Center and UNC Lineberger with focus on #LiverCancer | American Journal of Gastroenterology Deputy AE #RedJournal | ACG DigiPubs Chair | #LiverSky #GISky #MedSky
Turn It Up - the concert to raise colon cancer awareness put on by @amcollegegastro.bsky.social
Enjoying this beautiful performance by Michael Franti
Tune in here: gi.org/concert/
Enjoying this beautiful performance by Michael Franti
Tune in here: gi.org/concert/
March 27, 2025 at 12:23 AM
Turn It Up - the concert to raise colon cancer awareness put on by @amcollegegastro.bsky.social
Enjoying this beautiful performance by Michael Franti
Tune in here: gi.org/concert/
Enjoying this beautiful performance by Michael Franti
Tune in here: gi.org/concert/
December 9, 2024 at 6:02 PM
What do hepatic encephalopathy and irritable bowel syndrome have in common?
Read this hot take from @jasmohanbajaj.bsky.social and @markpimentelmd.bsky.social in #AJG on whether HE is the original disorder of gut brain interaction (DGBI)
#GISky #LiverSky
Link: journals.lww.com/ajg/fulltext...
Read this hot take from @jasmohanbajaj.bsky.social and @markpimentelmd.bsky.social in #AJG on whether HE is the original disorder of gut brain interaction (DGBI)
#GISky #LiverSky
Link: journals.lww.com/ajg/fulltext...
December 9, 2024 at 6:00 PM
What do hepatic encephalopathy and irritable bowel syndrome have in common?
Read this hot take from @jasmohanbajaj.bsky.social and @markpimentelmd.bsky.social in #AJG on whether HE is the original disorder of gut brain interaction (DGBI)
#GISky #LiverSky
Link: journals.lww.com/ajg/fulltext...
Read this hot take from @jasmohanbajaj.bsky.social and @markpimentelmd.bsky.social in #AJG on whether HE is the original disorder of gut brain interaction (DGBI)
#GISky #LiverSky
Link: journals.lww.com/ajg/fulltext...
Tumor seeding is a dreaded complication of biopsy for HCC. But how common is it?
A systematic review in @amcollegegastro.bsky.social #AmJGastro reports a rate of tumor seeding of 0.62% with even lower rates in recent years
#LiverSky
Link: journals.lww.com/ajg/abstract...
A systematic review in @amcollegegastro.bsky.social #AmJGastro reports a rate of tumor seeding of 0.62% with even lower rates in recent years
#LiverSky
Link: journals.lww.com/ajg/abstract...
November 27, 2024 at 2:05 PM
Tumor seeding is a dreaded complication of biopsy for HCC. But how common is it?
A systematic review in @amcollegegastro.bsky.social #AmJGastro reports a rate of tumor seeding of 0.62% with even lower rates in recent years
#LiverSky
Link: journals.lww.com/ajg/abstract...
A systematic review in @amcollegegastro.bsky.social #AmJGastro reports a rate of tumor seeding of 0.62% with even lower rates in recent years
#LiverSky
Link: journals.lww.com/ajg/abstract...
There have been a lot of recent changes in the world of MASLD - how to make sense of it all?!
Never fear. Neha Shah and Arun Sanyal provide us with a pragmatic approach in @amcollegegastro.bsky.social #AJG
#GISky #LiverSky #MedSky
Link: journals.lww.com/ajg/citation...
Never fear. Neha Shah and Arun Sanyal provide us with a pragmatic approach in @amcollegegastro.bsky.social #AJG
#GISky #LiverSky #MedSky
Link: journals.lww.com/ajg/citation...
November 25, 2024 at 1:46 PM
There have been a lot of recent changes in the world of MASLD - how to make sense of it all?!
Never fear. Neha Shah and Arun Sanyal provide us with a pragmatic approach in @amcollegegastro.bsky.social #AJG
#GISky #LiverSky #MedSky
Link: journals.lww.com/ajg/citation...
Never fear. Neha Shah and Arun Sanyal provide us with a pragmatic approach in @amcollegegastro.bsky.social #AJG
#GISky #LiverSky #MedSky
Link: journals.lww.com/ajg/citation...
Need more fodder to motivate yourself or your colleagues to do that early diagnostic paracentesis?
New in @amcollegegastro.bsky.social #AJG, meta-analysis showing that diagnostic paracentesis within 12 hours improves mortality, shortens LOS and reduces AKI.
Link: journals.lww.com/ajg/pages/ar...
New in @amcollegegastro.bsky.social #AJG, meta-analysis showing that diagnostic paracentesis within 12 hours improves mortality, shortens LOS and reduces AKI.
Link: journals.lww.com/ajg/pages/ar...
November 22, 2024 at 12:15 PM
Need more fodder to motivate yourself or your colleagues to do that early diagnostic paracentesis?
New in @amcollegegastro.bsky.social #AJG, meta-analysis showing that diagnostic paracentesis within 12 hours improves mortality, shortens LOS and reduces AKI.
Link: journals.lww.com/ajg/pages/ar...
New in @amcollegegastro.bsky.social #AJG, meta-analysis showing that diagnostic paracentesis within 12 hours improves mortality, shortens LOS and reduces AKI.
Link: journals.lww.com/ajg/pages/ar...
Incredibly important numbers to keep in mind as we’re caring for patients with cirrhosis to frame our discussions with patients and families and involvement of palliative care
@nnekauferemd.bsky.social discusses important solutions to facilitate patient-centered care at AASLD #TLM24
@nnekauferemd.bsky.social discusses important solutions to facilitate patient-centered care at AASLD #TLM24
November 18, 2024 at 1:53 AM
Incredibly important numbers to keep in mind as we’re caring for patients with cirrhosis to frame our discussions with patients and families and involvement of palliative care
@nnekauferemd.bsky.social discusses important solutions to facilitate patient-centered care at AASLD #TLM24
@nnekauferemd.bsky.social discusses important solutions to facilitate patient-centered care at AASLD #TLM24
Do nutritional interventions benefit patients with alcohol associated hepatitis?
Sasha Deutsch-Link discusses that evidence is weak but reasonable to recommend given that it’s unlikely to be harmful
AASLD #TLM24
Sasha Deutsch-Link discusses that evidence is weak but reasonable to recommend given that it’s unlikely to be harmful
AASLD #TLM24
November 18, 2024 at 1:24 AM
Do nutritional interventions benefit patients with alcohol associated hepatitis?
Sasha Deutsch-Link discusses that evidence is weak but reasonable to recommend given that it’s unlikely to be harmful
AASLD #TLM24
Sasha Deutsch-Link discusses that evidence is weak but reasonable to recommend given that it’s unlikely to be harmful
AASLD #TLM24
I’m a big fan of this conference venue
November 18, 2024 at 12:41 AM
I’m a big fan of this conference venue
Amazing! @amcollegegastro.bsky.social is now on @bsky.app
November 17, 2024 at 7:32 PM
Amazing! @amcollegegastro.bsky.social is now on @bsky.app
Great look into the future on HCC surveillance by George Ioannou at AASLD #TLM24
Seems likely that blood based biomarkers and aMRI will play some role but, despite its significant flaws, ultrasound has so far stood the test of time
Seems likely that blood based biomarkers and aMRI will play some role but, despite its significant flaws, ultrasound has so far stood the test of time
November 16, 2024 at 2:45 PM
Great look into the future on HCC surveillance by George Ioannou at AASLD #TLM24
Seems likely that blood based biomarkers and aMRI will play some role but, despite its significant flaws, ultrasound has so far stood the test of time
Seems likely that blood based biomarkers and aMRI will play some role but, despite its significant flaws, ultrasound has so far stood the test of time
What is the risk of progression to liver disease with high risk alcohol use?
Ponni Perumalswami shares natural history and modifiable risk factors at #TLM2024
Ponni Perumalswami shares natural history and modifiable risk factors at #TLM2024
November 15, 2024 at 5:10 PM
What is the risk of progression to liver disease with high risk alcohol use?
Ponni Perumalswami shares natural history and modifiable risk factors at #TLM2024
Ponni Perumalswami shares natural history and modifiable risk factors at #TLM2024
One AASLD #TLM2024 session that I'm eagerly awaiting is the debate on hepatologists prescribing systemic therapy for HCC
With neoadjuvant, adjuvant and combination therapies potentially on the horizon, there's a compelling supply/demand argument but lots of barriers
Should be interesting...
With neoadjuvant, adjuvant and combination therapies potentially on the horizon, there's a compelling supply/demand argument but lots of barriers
Should be interesting...
November 13, 2024 at 7:20 PM
One AASLD #TLM2024 session that I'm eagerly awaiting is the debate on hepatologists prescribing systemic therapy for HCC
With neoadjuvant, adjuvant and combination therapies potentially on the horizon, there's a compelling supply/demand argument but lots of barriers
Should be interesting...
With neoadjuvant, adjuvant and combination therapies potentially on the horizon, there's a compelling supply/demand argument but lots of barriers
Should be interesting...
Did you know...
There are nifty one page summaries of selected ACG guidelines available at gi.org/guidelines
Just click on the "Summary" tab under the guidelines
Here are some examples with many more in development
#GISky #LiverSky
There are nifty one page summaries of selected ACG guidelines available at gi.org/guidelines
Just click on the "Summary" tab under the guidelines
Here are some examples with many more in development
#GISky #LiverSky
November 13, 2024 at 4:04 PM
Did you know...
There are nifty one page summaries of selected ACG guidelines available at gi.org/guidelines
Just click on the "Summary" tab under the guidelines
Here are some examples with many more in development
#GISky #LiverSky
There are nifty one page summaries of selected ACG guidelines available at gi.org/guidelines
Just click on the "Summary" tab under the guidelines
Here are some examples with many more in development
#GISky #LiverSky
Tapper = Ray Kinsella
November 12, 2024 at 3:12 AM
Tapper = Ray Kinsella
How much do you worry about LIRADS-3 and LR-4 lesions in patients with cirrhosis?
HCC incidence rate 110/1000 person-year in patients with LR-3 lesions and 420/1000 for LR-4 lesions
🗝️ importance of close surveillance
Link: journals.lww.com/ajg/fulltext...
Podcast: webfiles.gi.org/podcasts/ajg...
HCC incidence rate 110/1000 person-year in patients with LR-3 lesions and 420/1000 for LR-4 lesions
🗝️ importance of close surveillance
Link: journals.lww.com/ajg/fulltext...
Podcast: webfiles.gi.org/podcasts/ajg...
November 12, 2024 at 3:03 AM
How much do you worry about LIRADS-3 and LR-4 lesions in patients with cirrhosis?
HCC incidence rate 110/1000 person-year in patients with LR-3 lesions and 420/1000 for LR-4 lesions
🗝️ importance of close surveillance
Link: journals.lww.com/ajg/fulltext...
Podcast: webfiles.gi.org/podcasts/ajg...
HCC incidence rate 110/1000 person-year in patients with LR-3 lesions and 420/1000 for LR-4 lesions
🗝️ importance of close surveillance
Link: journals.lww.com/ajg/fulltext...
Podcast: webfiles.gi.org/podcasts/ajg...